AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10471981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (12 mg oral dose) administered 2.5 hours after meal
Number of subjects: 18
Study 10471981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (12 mg oral dose) administered with a continued 4-hour postdose fast
Number of subjects: 18
Study 8723588 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg
Number of subjects: 31
Study 8723588 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU/kg
Number of subjects: 31
Study 8723588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8723588 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (both dosages)
Number of subjects: 31
Study 1332526 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Involvement (PI) condition
Number of subjects: 84
Study 1332526 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation (R) condition
Number of subjects: 84
Study 1332526 — intervention group
Group type: EXPERIMENTAL
Intervention: No Treatment (NT) condition
Number of subjects: 84
Study 1332526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 6364908 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides (gentamicin and tobramycin)
Number of subjects: 214
Study 6364908 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise discriminant analysis
Number of subjects: 214
Study 6364908 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation generated from discriminant analysis
Number of subjects: 214
Study 6364908 — intervention group
Group type: COMPARATOR
Intervention: Factors not significantly contributing to nephrotoxicity risk
Number of subjects: 214
Study 31764900 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural food-based fiber solution
Number of subjects: 46
Study 30196723 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic blue light exposure for 30 minutes
Number of subjects: 14
Study 30196723 — intervention group
Group type: COMPARATOR
Intervention: Control light (blue light with a filter foil) for 30 minutes
Number of subjects: 14
Study 26892399 — intervention group
Group type: EXPERIMENTAL
Intervention: Echium oil (EO) 5 g ALA + 2 g SDA daily for 8 weeks
Number of subjects: 85
Study 26892399 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed oil (LO) 5 g ALA daily for 8 weeks
Number of subjects: 85
Study 26892399 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (FO)
Number of subjects: 85
Study 26892399 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 85
Study 23302145 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based parenting programme for parents of preschool children
Number of subjects: 0
Study 22370992 — intervention group
Group type: EXPERIMENTAL
Intervention: Large doses of arachidonic acid (ARA) added to docosahexaenoic acid (DHA) (n = 7)
Number of subjects: 13
Study 22370992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 13
Study 20200197 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1a
Number of subjects: 180
Study 20200197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 17394956 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol plus rapamycin-eluting stent (ERES)
Number of subjects: 502
Study 17394956 — intervention group
Group type: COMPARATOR
Intervention: Rapamycin-eluting stent (RES)
Number of subjects: 502
Study 15644650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 6 mL/kg predicted body weight
Number of subjects: 111
Study 15644650 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume of 12 mL/kg predicted body weight
Number of subjects: 111
Study 11824860 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic volume contraction (induced by furosemide infusion and replaced by 5% isotonic glucose infusion)
Number of subjects: 24
Study 11824860 — intervention group
Group type: COMPARATOR
Intervention: Control group (salt-sensitive subjects)
Number of subjects: 24
Study 11824860 — intervention group
Group type: COMPARATOR
Intervention: Control group (salt-resistant subjects)
Number of subjects: 24
Study 10674679 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 150
Study 10674679 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-mefloquine
Number of subjects: 150
Study 7744192 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxamine (10 mg)
Number of subjects: 10
Study 7744192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1963135 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (10 mg)
Number of subjects: 981
Study 1963135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 981
Study 6291889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg IV bolus)
Number of subjects: 0
Study 6291889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (0.12 mg/ml in vitro)
Number of subjects: 0
Study 6291889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (600 mg over 12 hours)
Number of subjects: 0
Study 6291889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg IV bolus)
Number of subjects: 0
Study 6291889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (100 mg IV bolus)
Number of subjects: 0
Study 6291889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and Ranitidine (in vitro antifibrinolytic effect)
Number of subjects: 0
Study 31802740 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated obstructive sleep apnea (OSA)
Number of subjects: 287191
Study 31802740 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient care
Number of subjects: 287191
Study 31802740 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions
Number of subjects: 287191
Study 31802740 — intervention group
Group type: COMPARATOR
Intervention: Matched control patients without sleep-disordered breathing
Number of subjects: 287191
Study 30019768 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning education program (weekly 90‐minute sessions for 24 weeks)
Number of subjects: 84
Study 30019768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active learning intervention)
Number of subjects: 84
Study 27380049 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Tube LTS II™ size 2
Number of subjects: 56
Study 27380049 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway Supreme™ size 2
Number of subjects: 56
Study 24270967 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverberation time of 0.7 s
Number of subjects: 16
Study 24270967 — intervention group
Group type: COMPARATOR
Intervention: Non-reverberated condition
Number of subjects: 16
Study 22289659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PTH134 1 mg with 200 mg 5-CNAC
Number of subjects: 32
Study 22289659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PTH134 2.5 mg with 200 mg 5-CNAC
Number of subjects: 32
Study 22289659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PTH134 5 mg with 200 mg 5-CNAC
Number of subjects: 32
Study 22289659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PTH134 10 mg with 200 mg 5-CNAC
Number of subjects: 32
Study 22289659 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg sc
Number of subjects: 32
Study 22289659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22289659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PTH134 2.5 mg with 100 mg 5-CNAC
Number of subjects: 32
Study 22289659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PTH134 5 mg with 100 mg 5-CNAC
Number of subjects: 32
Study 20584172 — intervention group
Group type: EXPERIMENTAL
Intervention: sFas levels in overweight/obese men (2.42 ng mL(‐1))
Number of subjects: 876
Study 20584172 — intervention group
Group type: EXPERIMENTAL
Intervention: sFas levels in men with hyperlipidaemia (2.34 ng mL(‐1))
Number of subjects: 876
Study 20584172 — intervention group
Group type: EXPERIMENTAL
Intervention: sFas levels in men with three to four metabolic risk factors (2.39 ng dL(‐1))
Number of subjects: 876
Study 20584172 — intervention group
Group type: EXPERIMENTAL
Intervention: sFas levels in men with two metabolic risk factors (2.28 ng dL(‐1))
Number of subjects: 876
Study 20584172 — intervention group
Group type: EXPERIMENTAL
Intervention: sFas levels in men with one metabolic risk factor (2.24 ng dL(‐1))
Number of subjects: 876
Study 20584172 — intervention group
Group type: EXPERIMENTAL
Intervention: sFas levels in men with none of the four metabolic risk factors (2.11 ng dL(‐1))
Number of subjects: 876
Study 20584172 — intervention group
Group type: EXPERIMENTAL
Intervention: sFas levels in women
Number of subjects: 876
Study 17366526 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring techniques (individualized counseling about fluid and caffeine intake, quick pelvic floor muscle contraction, voiding frequency, and management of constipation)
Number of subjects: 224
Study 17366526 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring techniques
Number of subjects: 224
Study 17366526 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 224
Study 15764328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile torso display with 15 tactor linear display
Number of subjects: 0
Study 15764328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile torso display
Number of subjects: 0
Study 12121537 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi Purpose Plus System (group I)
Number of subjects: 12
Study 12121537 — intervention group
Group type: COMPARATOR
Intervention: Single Bond adhesive (group II)
Number of subjects: 12
Study 9867134 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting condition
Number of subjects: 40
Study 9867134 — intervention group
Group type: COMPARATOR
Intervention: Nonfasting condition
Number of subjects: 40
Study 7615030 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes-open condition
Number of subjects: 25
Study 7615030 — intervention group
Group type: COMPARATOR
Intervention: Eyes-closed condition
Number of subjects: 25
Study 2710995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal sterilization (n = 7)
Number of subjects: 14
Study 2710995 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective intestinal decontamination (n = 7)
Number of subjects: 14
Study 2710995 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 14
Study 681526 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment strategies
Number of subjects: 239
Study 681526 — intervention group
Group type: COMPARATOR
Intervention: Control treatment strategy
Number of subjects: 239
Study 30646835 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% 1RM
Number of subjects: 13
Study 30646835 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% 1RM
Number of subjects: 13
Study 29258591 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic support with community dialogue
Number of subjects: 0
Study 29258591 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic support without community dialogue
Number of subjects: 0
Study 29258591 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25996534 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid application after PELD
Number of subjects: 100
Study 25996534 — intervention group
Group type: COMPARATOR
Intervention: Saline treatment after PELD
Number of subjects: 100
Study 23566344 — intervention group
Group type: EXPERIMENTAL
Intervention: Midlife COPD
Number of subjects: 2000
Study 23566344 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 2000
Study 23566344 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pulmonary diseases combined (COPD and asthma) diagnosed in midlife
Number of subjects: 2000
Study 23566344 — intervention group
Group type: COMPARATOR
Intervention: Both pulmonary diseases combined diagnosed later in life
Number of subjects: 2000
Study 21746979 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 241
Study 21746979 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 241
Study 19241215 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia presentation (Group I, n=34)
Number of subjects: 68
Study 19241215 — intervention group
Group type: COMPARATOR
Intervention: Case based discussion (Group II, n=34)
Number of subjects: 68
Study 16426098 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood-onset bipolar illness
Number of subjects: 0
Study 16426098 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first treatment
Number of subjects: 0
Study 16426098 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for treatment outcome data acquisition
Number of subjects: 0
Study 15232328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 60 mg/d)
Number of subjects: 123
Study 15232328 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (up to 400 mg IM testosterone cypionate biweekly)
Number of subjects: 123
Study 15232328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 11703431 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise consultation and standard exercise information
Number of subjects: 26
Study 11703431 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise information alone
Number of subjects: 26
Study 9205633 — intervention group
Group type: EXPERIMENTAL
Intervention: etidronate 400 mg/day
Number of subjects: 109
Study 9205633 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 109
Study 8094485 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of 0.3‐0.5 ml sterile water
Number of subjects: 40
Study 8094485 — intervention group
Group type: COMPARATOR
Intervention: Saline injections
Number of subjects: 40
Study 8094485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water group
Number of subjects: 40
Study 8094485 — intervention group
Group type: COMPARATOR
Intervention: Saline group
Number of subjects: 40
Study 8094485 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 8 months
Number of subjects: 40
Study 2959717 — intervention group
Group type: COMPARATOR
Intervention: rt-PA (0.75 mg/kg)
Number of subjects: 258
Study 2959717 — intervention group
Group type: COMPARATOR
Intervention: rt-PA (40 or 80 mg)
Number of subjects: 258
Study 2959717 — intervention group
Group type: EXPERIMENTAL
Intervention: single chain rt-PA (100 mg total)
Number of subjects: 258
Study 2959717 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 258
Study 29792839 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus a choice of nonpharmacologic pain management options (ambient music, etc.)
Number of subjects: 74
Study 29792839 — intervention group
Group type: COMPARATOR
Intervention: Standard care (ibuprofen 800 mg orally, lidocaine paracervical block, anticipatory guidance)
Number of subjects: 74
Study 29792839 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus a choice of nonpharmacologic pain management options
Number of subjects: 74
Study 29792839 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 74
Study 26731446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 42
Study 26731446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25894960 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate treatment (group 1)
Number of subjects: 72
Study 25894960 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 72
Study 25191599 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 193
Study 25191599 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 193
Study 25191599 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 193
Study 20363690 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0
Study 20363690 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 18427045 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE with dermoscopy
Number of subjects: 1328
Study 18427045 — intervention group
Group type: COMPARATOR
Intervention: CSE without dermoscopy
Number of subjects: 1328
Study 17081269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 20
Study 17081269 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 20
Study 16083195 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai-made levonorgestrel pill (0.75 mg)
Number of subjects: 18
Study 16083195 — intervention group
Group type: COMPARATOR
Intervention: Hungarian levonorgestrel pill (0.75 mg)
Number of subjects: 18
Study 11283441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume single-set circuit (SSC; N = 12)
Number of subjects: 34
Study 11283441 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized high-volume multiple-set (MS; N = 12)
Number of subjects: 34
Study 11283441 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control (CON; N = 10)
Number of subjects: 34
Study 9401829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 2.5 mg
Number of subjects: 20
Study 9401829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 5 mg
Number of subjects: 20
Study 9401829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 10 mg
Number of subjects: 20
Study 9401829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 15 mg
Number of subjects: 20
Study 9401829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 20 mg
Number of subjects: 20
Study 9401829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 25 mg
Number of subjects: 20
Study 9401829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8099593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, 15 mg twice daily
Number of subjects: 25
Study 8099593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3543236 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (high-dose methotrexate, Adriamycin, BCD)
Number of subjects: 59
Study 3543236 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (control group)
Number of subjects: 59
Study 31626314 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DFT)
Number of subjects: 499211
Study 28714771 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Static Stretching (ASS)
Number of subjects: 60
Study 28714771 — intervention group
Group type: COMPARATOR
Intervention: Warming-up exercise alone (Control)
Number of subjects: 60
Study 27283187 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique absorbable intradermic stitch (Group A)
Number of subjects: 208
Study 27283187 — intervention group
Group type: COMPARATOR
Intervention: Traditional closure technique (non-absorbable separated stitches) (Group B)
Number of subjects: 208
Study 24699554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) injection
Number of subjects: 19
Study 24699554 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) injection
Number of subjects: 19
Study 22883272 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin Injection
Number of subjects: 388
Study 22883272 — intervention group
Group type: COMPARATOR
Intervention: Danshen Injection
Number of subjects: 388
Study 22883272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 388
Study 20692030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (2 mL, three oral doses at 6, 10, and 14 weeks of age)
Number of subjects: 5468
Study 20692030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5468
Study 20692030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine
Number of subjects: 5468
Study 18657196 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50 (LM50)
Number of subjects: 120
Study 18657196 — intervention group
Group type: COMPARATOR
Intervention: Human insulin mix 50
Number of subjects: 120
Study 18657196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study 16326239 — intervention group
Group type: EXPERIMENTAL
Intervention: Effleurage massage for 5 minutes
Number of subjects: 12
Study 16326239 — intervention group
Group type: COMPARATOR
Intervention: Rest for 5 minutes
Number of subjects: 12
Study 11985407 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased total fat intake
Number of subjects: 1182
Study 11985407 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased carbohydrate intake
Number of subjects: 1182
Study 11985407 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased total protein intake
Number of subjects: 1182
Study 11985407 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased saturated fat intake
Number of subjects: 1182
Study 11985407 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased unsaturated fat intake
Number of subjects: 1182
Study 11985407 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased myristic fatty acid intake
Number of subjects: 1182
Study 9862296 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound therapy at 1.5W/cm2 (group A)
Number of subjects: 18
Study 9862296 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound therapy at 0.8W/cm2 (group B)
Number of subjects: 18
Study 9862296 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound therapy at 0.0W/cm2 (group C)
Number of subjects: 18
Study 8595799 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2146853 — intervention group
Group type: EXPERIMENTAL
Intervention: danazol
Number of subjects: 12
Study 2146853 — intervention group
Group type: COMPARATOR
Intervention: goserelin
Number of subjects: 12
Study 1070948 — intervention group
Group type: EXPERIMENTAL
Intervention: delta9-THC
Number of subjects: 74
Study 1070948 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT
Number of subjects: 74
Study 1070948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74